The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) (Nanbru et al., 1997; Stoneley et al., 1998) and thus cmyc protein synthesis can be initiated by a capindependent as well as a cap-dependent mechanism . In cell lines derived from patients with multiple myeloma (MM) there is aberrant translational regulation of c-myc and this correlates with a C-T mutation in the c-myc-IRES . RNA derived from the mutant IRES displays enhanced binding of protein factors . Here we show that the same mutation is present in 42% of bone marrow samples obtained from patients with MM, but was not present in any of 21 controls demonstrating a strong correlation between this mutation and the disease. In a tissue culture based assay, the mutant version of the c-myc-IRES was more active in all cell types tested, but showed the greatest activity in a cell line derived from a patient with MM. Our data demonstrate that a single mutation in the c-myc-IRES is sucient to cause enhanced initiation of translation via internal ribosome entry and represents a novel mechanism of oncogenesis. Oncogene (2000) 19, 4437 ± 4440.
Keywords: c-myc; multiple myeloma; internal ribosome entry segment; translation initiation Initiation of translation can occur by two dierent mechanisms; cap-dependent initiation which involves the binding of the eukaryotic initiation factor (eIF) complex 4F to the 7 methyl G cap at the 5' end of the mRNA and ribosomal scanning (Gray and Wickens, 1998; Pain, 1996) or internal ribosome entry. The latter is mediated by structured regions of RNA termed internal ribosome entry segments (IRES), and these have the ability to direct ribosome binding some considerable distance (up to 1000 nts) from the 5' end of the message. IRESs were originally discovered in picornaviral mRNAs, but have now been identi®ed in a number of eukaryotic mRNAs, the protein products of which are involved in the control of cell growth including, FGF-2 (Vagner et al., 1995) , VEGF (Miller et al., 1998; Stein et al., 1998) , PDGF (Bernstein et al., 1997) and c-myc (Nanbru et al., 1997; Stoneley et al., 1998) and cell death Holcik et al., 1999) . In the case of c-myc we have shown that initiation of protein synthesis can occur by two distinct mechanisms; cap-dependent scanning and IRES mediated . Thus suggesting that control of translation is important in regulating cellular levels of c-myc in addition to the other mechanisms that have been described. These include alterations in rates of transcription of the mRNA, and the stability of both the mRNA and protein (Ross, 1995; Lee et al., 1998; LuÈ scher and Eisenmann, 1988; Shindo et al., 1993) . The number of levels that c-myc expression is controlled at is probably a re¯ection of the diverse cellular processes in which this proto-oncogene is thought to function e.g. cell proliferation, cell cycle progression and apoptosis (Evan and Littlewood, 1993; Dang, 1999) . It is not surprising therefore, that deregulation of c-myc is associated with a wide range of tumour types and this may occur by ampli®cation or chromosomal rearrangement (Neri et al., 1988; Pelicci et al., 1986; Schwab et al., 1986; Sumegi et al., 1985) . However, we have also shown that increased c-myc protein expression can occur from aberrant translational regulation West et al., 1995) . For example, in cell lines derived from patients with multiple myeloma (MM, an incurable disease which is characterized by bone marrow plasmacytosis, osteolytic lesions and secretion of a monoclonal immunoglobulin (Niesvizky et al., 1993) there is an up to 20-fold increase in c-myc protein levels that occurs by a translational mechanism . This increased c-myc protein expression in MM derived cell lines correlates with a C-T mutation in the region of cmyc DNA that contains the IRES . In this study experiments were performed to investigate whether the C-T mutation in the c-myc IRES identi®ed in the cell lines is also present in the bone marrow of MM patients and moreover, if the presence of the mutation alters translation initiation via the IRES.
Bone marrow derived mRNA from patients with MM, premalignant Monoclonal Gammopathy of uncertain signi®cance (MGUS) patients or controls with either non-MM disease or normal individuals, was reverse transcribed. Using oligonucleotides complementary to the P2 promoter of c-myc and to the 3' end of the 5' untranslated region (Figure 1a) , the c-myc IRES was ampli®ed by the polymerase chain reaction. Initially T-track sequencing was performed to identify those samples that contained the mutation (Figure 1b ). The sequence of this region is CCCTCTC in wild type samples and bands that correspond to two thymidines in this segment of DNA can clearly been seen in the control bone marrow samples (Figure 1b ). In the mutant samples the sequence is altered to CTCTCTC, and thus thymidines are now observed. Due to a slight compression in this region, the mutant and wild type sequences migrate to slightly dierent positions on the gel allowing them to be distinguished between in a mixed population. This is particularly fortuitous since all of the patient samples which scored positive for the mutation contained a mixture of both wild type and mutant sequence, and thus thymidines are observed at this position on the gel (Figure 1b) . The dierence in intensity in the bands that correspond to the presence of the mutation in the bone marrow samples re¯ects the fact that there were varying amount of MM plasma cells in this material. All those samples that scored positive were then subjected to full sequencing ( Figure  1c ). The results from the sequencing analysis are summarised in Table 1 . These show that the C-T mutation at position 2756 (numbering as in Watt et al., 1983) was identi®ed in 42% (8/19) MM patients, 20% (2/10) MGUS patients and was undetectable (0/21) in control patients. The dierence in allele distribution is chi squared 11.04 (P=0.004) across all three groups and 10.59 (P=0.001) for MM versus the controls. This indicates a strong association of the C-T mutation with MM. Blood samples were then analysed from an additional 20 patients with multiple myeloma and these all scored negative for the presence of the C-T mutation (data not shown) suggesting that the mutation is somatic rather than germ line.
To compare the activity of the mutant and wild type versions of the c-myc IRES, the region of DNA which contains the mutation was cloned into the dicistronic reporter vector pRF . This vector contains the Renilla and Fire¯y luciferase genes upstream and downstream respectively of a spacer region (Figure 2a ) . We have shown previously that insertion of the c-myc IRES into this intercistronic region results in a 50 ± 100-fold increase in the activity of the ®re¯y luciferase by internal ribosome entry (Stoneley et al., 1998) . The WT and MT versions of this dicistronic plasmid (pRMF and pRMFmt) were then transfected into a number of cell types. In all cells tested the mutant version of the c-myc IRES was more active than the wild type. Thus the presence of the mutation increased the activity of the luciferase reporter enzyme 1.5-fold in HeLa cells, 1.6-fold in a control SV40 transformed ®broblast line GM637, twofold in a control B-cell line derived from a normal individual, GM03201, whilst in the MM derived cell line, GM2132, the mutant version of the IRES was between 4 ± 6 times more active (Figure 2b) . We have shown previously that the eciency of c-myc IRESdriven translation varies widely between cells lines . However, the enhanced expression of the mutant is not simply a re¯ection of enhanced IRES expression in GM2132 cells. Thus the relative c-myc-IRES eciency when expressed as Chomczynski and Sacchi (1987) . After the removal of contaminating DNA the samples were incubated for 1 h with Moloney Murine Leukaemia Virus reverse transcriptase in a mixture containing 0.5 mM dNTPs, 10 mM DTT, 1 ml random hexamer primers (100 pmoles/ml) and 1 unit RNasin (Promega). Two ml of these samples were then used in a polymerase chain reaction. The Primers FP1 (5'-GCCGGATCCGGCCCTTTATAATGCGAC-3') and FP2 (5'-GTGGAATTCTGGTTTTCCACTACCCGAAA-3') were used to amplify c-myc exon 1 (2289 ± 2881). PCR reactions contained 10 ml 106PCR Buer (Advanced Biosystems), 10 ml MgCl 2 (25 mM), 1 ml dNTPs (10 mM of each of dATP, dCTP, dTTP, dGTP), 1 unit Taq DNA polymerase (Advanced Biosystems). The PCR reactions were carried out in a Techne DNA Thermal Cycler at 948C for 3 min followed by 37 cycles of (948C for 2 min, 638C for 3 min, 728C for 2 min) and 728C for 10 min All patient samples that scored positive were heterozygous for the mutation. Bone marrow aspirates were obtained from 19 consecutive patients with multiple myeloma and 10 patients with Monoclonal Gammopathy of uncertain signi®cance (MGUS) who were diagnosed according to standard clinical criteria. As controls, marrow samples were obtained from 21 age matched individuals who were undergoing investigations for other disorders, there were nine patients with Paget's disease, three patients with osteoporosis, one with megaloblastic anaemia and seven patients undergoing cytoscopy. All patients gave informed consent to participating in the study that was also approved by the local research ethical committee. There was no correlation with the Durie Salmon disease stage and the presence of the mutation the ratio of Fire¯y luciferase/Renilla luciferase in MM derived GM2132 cells has a value of 0.75, compared to 4 for HeLa, 1.6 for GM637 and 0.55 for GM03021. The presence of the mutation in the cmyc IRES causes the eciency of IRES mediated translation in the GM2132 cells to become comparable to that which we observe in HeLa cells where we ®nd that IRESs are most active Coldwell et al., 2000) . Since the major dierence in the mutant IRES function was observed in the MM derived cell line, it would suggest that trans-acting factors that are required for internal ribosome entry are more abundant in this cell line. In agreement with this we have shown previously that the MM derived cell line GM2132 expresses an altered repertoire of RNA binding proteins . By chemical and enzymatic probing of c-myc IRES RNA in conjunction with computer analysis, we have derived a structural model for the c-myc IRES (LeQuesne et al., submitted) . Using this model we predict that the C-T mutation may cause stabilization of a stem loop structure in the 3' end of the IRES (Figure 3) . We hypothesise that the increased expression from the C-T form of the c-myc IRES is likely to reside in an enhanced interaction of RNA binding proteins with this structurally altered region. In conclusion we have identi®ed a mutation in the c-myc IRES in the plasma cells isolated from bone marrow in 42% of MM patients samples and have shown in a tissue culture based assay that in a MM derived cell line, this mutation increases the expression of a downstream reporter by up to sixfold. Clearly this is not the only mechanism to increase c-myc expression since 58% of samples do not contain this mutation. However, we have found some additional mutations in the c-myc IRES in bone marrow material obtained from these patients and those currently under investigation. Several examples exist in viral systems which show that single mutations are capable of altering IRES function, for example a single substitution in the FMDV-IRES has been shown to increase the degree of internal ribosome entry up to ®vefold (Martinez-Salas et al., 1993) . However, this is the ®rst example of a mutation in a eukaryotic IRES leading to increased translation initiation by internal ribosome entry. This represents a novel mechanism of c-myc de-regulation and has profound implications in tumorigenesis. . Activities of the wild type and mutant version of the c-myc IRES in a range of cell lines. All cells were obtained from NIGMS. Cells were grown in RPMI (GM2132, GM03201) or DMEM (HeLa, GM637) containing 10% foetal calf serum in a humidi®ed atmosphere containing 5% CO 2 . Cells were transfected with pRMF (that contains the wild type IRES; Stoneley et al., 1998) or pRMFmt and the bgalactosidase encoding construct pcDNA3. 1/HisB/Lacz (Invitrogen) using either calcium phosphate DNA co-precipitation (Auscbel, 1987) or by electroporation (GM2132 and GM03201) using a BioRad Gene pulser. Cells were harvested after 48 h and luciferase expression was determined using the dual-luciferase assay system (Promega). b-galactosidase expression was determined using a Galactolight plus system (Tropix). Both activities were measured in an Opticomp-1 Luminometer (MGM instruments). Variations in transfection eciency were corrected by normalizing luciferase activity to b-galactosidase activity. All assays were performed in triplicate on three independent occasions Figure 3 The increased activity of the c-myc IRES is likely to be caused by a structural change. We have derived a secondary structure model for the c-myc IRES (LeQuesne et al., submitted) and using this model we predict that the C-T mutation would result in the insertion of an extra stem loop region in the 3' end of the UTR Oncogene
